These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 14981107)

  • 1. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Kirchner H; Jonas U; Bergmann L; Schott H; Heynemann H; Fornara P; Loening SA; Roigas J; Müller SC; Bodenstein H; Pomer S; Metzner B; Rebmann U; Oberneder R; Siebels M; Wandert T; Puchberger T; Reitz M;
    J Clin Oncol; 2004 Apr; 22(7):1188-94. PubMed ID: 14981107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Kirchner H; Rebmann U; Soder M; Gertenbach U; Siebels M; Roigas J; Raschke R; Salm S; Schwindl B; Müller SC; Hauser S; Leiber C; Huland E; Heinzer H; Siemer S; Metzner B; Heynemann H; Fornara P; Reitz M
    Br J Cancer; 2006 Aug; 95(4):463-9. PubMed ID: 16909131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.
    Atzpodien J; Hoffmann R; Franzke M; Stief C; Wandert T; Reitz M
    Cancer; 2002 Sep; 95(5):1045-50. PubMed ID: 12209689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Schmitt E; Gertenbach U; Fornara P; Heynemann H; Maskow A; Ecke M; Wöltjen HH; Jentsch H; Wieland W; Wandert T; Reitz M;
    Br J Cancer; 2005 Mar; 92(5):843-6. PubMed ID: 15756254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
    Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
    J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
    Négrier S; Caty A; Lesimple T; Douillard JY; Escudier B; Rossi JF; Viens P; Gomez F
    J Clin Oncol; 2000 Dec; 18(24):4009-15. PubMed ID: 11118461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma.
    Atzpodien J; Wandert T; Reitz M
    Crit Rev Oncol Hematol; 2005 Sep; 55(3):193-9. PubMed ID: 16115777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
    J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
    Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
    Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
    Vogelzang NJ; Lipton A; Figlin RA
    J Clin Oncol; 1993 Sep; 11(9):1809-16. PubMed ID: 8355047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
    Escudier B; Bellmunt J; Négrier S; Bajetta E; Melichar B; Bracarda S; Ravaud A; Golding S; Jethwa S; Sneller V
    J Clin Oncol; 2010 May; 28(13):2144-50. PubMed ID: 20368553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
    Ravaud A; Audhuy B; Gomez F; Escudier B; Lesimple T; Chevreau C; Douillard JY; Caty A; Geoffrois L; Ferrero JM; Linassier C; Drevon M; Négrier S
    J Clin Oncol; 1998 Aug; 16(8):2728-32. PubMed ID: 9704724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
    Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
    J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.